FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080787533> ?p ?o ?g. }

• W2080787533 endingPage "276" @default.
• W2080787533 startingPage "275" @default.
• W2080787533 abstract "To identify amino acids that might be involved in discriminating guanosine-3′,5′-cyclic phosphate (cGMP) towards adenosine-3′,5′-cyclic phosphate (cAMP) binding in the cAMP-specific phosphodiesterases, alignments of different human cyclic nucleotide phosphodiesterases (PDEs) were performed. Eight amino acid residues that are highly conserved in the cAMP-hydrolysing phosphodiesterases (PDE1, PDE3, PDE4, PDE7, PDE8) and that did not show any homologies to the cGMP-specific phosphodiesterases (PDE5, PDE6, PDE9) were selected from these alignments. Using the technique of site-directed mutagenesis, derivatives of PDE4A carrying single mutations at these conserved residues (amino acid positions are given according to the human PDE4A isoform HSPDE4A4B; accession number L20965) were generated and expressed in COS1 cells. The expression products were characterised with regard to cAMP and cGMP hydrolysis and sensitivity towards type-specific inhibitors. The mutation of Phe484 toward Tyr, Ala590 toward Cys, Leu391 and Val501 towards Ala had no significant influence on substrate affinity or specificity. However, the exchange of Trp375 and Trp605 for aliphatic residues abolished catalytic activity and the exchange of Pro595 for Ile led to sevenfold decrease of substrate affinity and an 14-fold decrease of the affinity towards the PDE4-specific inhibitor 4-[3-(cyclopentoxyl)-4-methoxyphenyl]-2-pyrrolidone (rolipram). Both effects may provide evidence for a structural importance of Trp375, Trp605 and Pro595 for PDE function. By exchanging the aspartate residue for asparagine or alanine at position 440 of the human PDE4A4B isoform, the substrate specificity was altered from the highly specific cAMP hydrolysis to an equally efficient cAMP and cGMP binding and hydrolysis. In addition, the IC50 values for common PDE4-specific inhibitors like rolipram, N-(3,5-dichlorpyrid-4-yl)-3-cyclopentyl-oxy-4-methoxy-benzamide (RPR-73401) and 8-methoxy-5-N-propyl-3-methyl-1-ethyl-imidazo[1,5-a]-pyrido[3,2-e]-pyrazinone (D-22888) were dramatically increased. These results demonstrate an important role of the aspartate at position 440 in determining substrate specificity and inhibitor susceptibility of PDE4A. The strong conservation of this residue suggests that Asp440 may play a similar role in other cAMP-PDEs." @default.
• W2080787533 created "2016-06-24" @default.
• W2080787533 creator A5015670807 @default.
• W2080787533 creator A5067974727 @default.
• W2080787533 date "2008-06-01" @default.
• W2080787533 modified "2023-09-26" @default.
• W2080787533 title "COMPOSITE APPROACH: A METHOD FOR ANALYZING EFFICACY DATA IN CLINICAL TRIALS OF ANTIPSYCHOTIC MEDICATIONS THAT ACCOUNTS FOR DROPOUT AND DOES NOT IMPUTE DATA" @default.
• W2080787533 doi "https://doi.org/10.1016/s0920-9964(08)70830-2" @default.
• W2080787533 hasPublicationYear "2008" @default.
• W2080787533 type Work @default.
• W2080787533 sameAs 2080787533 @default.
• W2080787533 citedByCount "0" @default.
• W2080787533 crossrefType "journal-article" @default.
• W2080787533 hasAuthorship W2080787533A5015670807 @default.
• W2080787533 hasAuthorship W2080787533A5067974727 @default.
• W2080787533 hasConcept C104317684 @default.
• W2080787533 hasConcept C181199279 @default.
• W2080787533 hasConcept C185592680 @default.
• W2080787533 hasConcept C2776958096 @default.
• W2080787533 hasConcept C2779856020 @default.
• W2080787533 hasConcept C515207424 @default.
• W2080787533 hasConcept C53345823 @default.
• W2080787533 hasConcept C55493867 @default.
• W2080787533 hasConcept C58141971 @default.
• W2080787533 hasConcept C62826618 @default.
• W2080787533 hasConcept C79418042 @default.
• W2080787533 hasConceptScore W2080787533C104317684 @default.
• W2080787533 hasConceptScore W2080787533C181199279 @default.
• W2080787533 hasConceptScore W2080787533C185592680 @default.
• W2080787533 hasConceptScore W2080787533C2776958096 @default.
• W2080787533 hasConceptScore W2080787533C2779856020 @default.
• W2080787533 hasConceptScore W2080787533C515207424 @default.
• W2080787533 hasConceptScore W2080787533C53345823 @default.
• W2080787533 hasConceptScore W2080787533C55493867 @default.
• W2080787533 hasConceptScore W2080787533C58141971 @default.
• W2080787533 hasConceptScore W2080787533C62826618 @default.
• W2080787533 hasConceptScore W2080787533C79418042 @default.
• W2080787533 hasIssue "1-3" @default.
• W2080787533 hasLocation W20807875331 @default.
• W2080787533 hasOpenAccess W2080787533 @default.
• W2080787533 hasPrimaryLocation W20807875331 @default.
• W2080787533 hasRelatedWork W1583794602 @default.
• W2080787533 hasRelatedWork W1697304395 @default.
• W2080787533 hasRelatedWork W1942347535 @default.
• W2080787533 hasRelatedWork W1959582949 @default.
• W2080787533 hasRelatedWork W1988408001 @default.
• W2080787533 hasRelatedWork W1995778722 @default.
• W2080787533 hasRelatedWork W2015724424 @default.
• W2080787533 hasRelatedWork W2020117331 @default.
• W2080787533 hasRelatedWork W2114226988 @default.
• W2080787533 hasRelatedWork W3148870866 @default.
• W2080787533 hasVolume "102" @default.
• W2080787533 isParatext "false" @default.
• W2080787533 isRetracted "false" @default.
• W2080787533 magId "2080787533" @default.
• W2080787533 workType "article" @default.